Physician profile
Raul Valcarcel
NPI 1831223510
$19,670.12
in general payments reported to CMS, 2019-2025
57 companies · $3,090 in 2025
The $3,090 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,774 · 2020: $1,667 · 2021: $2,753 · 2022: $3,186 · 2023: $2,554 · 2024: $3,645 · 2025: $3,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,278 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,277.61 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,944.22 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $2,773.19 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,993.94 | 2020-2025 | Qulipta, Ubrelvy, Vraylar |
| Amgen INC. | $1,779.12 | 2019-2025 | Repatha, Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,009.96 | 2022-2025 | Caplyta |
| Novo Nordisk INC | $879.27 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $851.10 | 2019-2025 | |
| Glaxosmithkline, LLC. | $773.06 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Phathom Pharmaceuticals, INC. | $602.23 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $569.37 | 2021 | |
| Axsome Therapeutics, INC. | $557.28 | 2022-2025 | Auvelity, Sunosi, Symbravo |
| Lilly USA, LLC | $466.07 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amarin Pharma, INC. | $454.01 | 2019-2022 | |
| Pfizer INC. | $333.43 | 2019-2025 | |
| Nevro Corp. | $323.53 | 2021-2022 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Valcarcel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.